GLOW (GHK-Cu / TB-500 / BPC-157)

The GLOW combination’s pharmacological rationale rests on three non-redundant regenerative axes operating in parallel — each addressing a distinct component of tissue repair, healing, and anti-aging biology. The combined mechanism is designed to address ECM remodeling and gene-level repair (GHK-Cu), cell migration and neovascularization (TB-500), and cytoprotection with organ-level healing (BPC-157) simultaneously, producing a broader regenerative effect than any single agent alone.

Component 1: GHK-Cu (Glycine-L-Histidine-L-Lysine Copper Complex) — 50 mg

GHK-Cu is a naturally occurring human plasma tripeptide (Gly-His-Lys) complexed with copper (Cu²⁺) that was first isolated from human plasma by Dr. Loren Pickart in 1973. Its endogenous plasma concentration declines dramatically with age — from approximately 200 ng/mL at age 20 to less than 80 ng/mL by age 60 — a decline temporally associated with deterioration in wound healing, collagen synthesis, and regenerative capacity.

Gene Expression Reprogramming

GHK-Cu is the most extensively characterized component of the GLOW formulation from a mechanistic standpoint:

• GHK-Cu has been demonstrated to modulate the expression of over 4,000 human genes — approximately 31.2% of the human genome — resetting gene expression patterns toward a profile associated with younger, healthier tissue states, including upregulation of anti-inflammatory, antioxidant, and tissue repair pathways
• The peptide activates the TGF-β (transforming growth factor-beta) pathway, upregulating collagen I, collagen III, elastin, and glycosaminoglycan synthesis — the foundational structural proteins of dermal and connective tissue ECM
• SPARC (secreted protein acidic and rich in cysteine) upregulation drives collagen remodeling and tissue organization; this effect is distinct from and complementary to TB-500’s cell migration mechanism
• GHK-Cu activates antioxidant defense genes including SOD1, SOD2 (superoxide dismutases), and catalase, conferring cellular protection against reactive oxygen species (ROS)-mediated damage
• Anti-inflammatory gene modulation: GHK-Cu suppresses NF-κB activity and downregulates pro-inflammatory cytokine expression (TNF-α, IL-6, IL-1β), providing a molecular anti-inflammatory mechanism complementary to BPC-157’s NO-mediated pathway

Copper-Dependent Enzymatic Activity

• The Cu²⁺ component of GHK-Cu is biologically active — copper is a required cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers within the ECM, directly contributing to tissue strength and structural integrity
• Copper chelation and delivery to local tissues by the GHK tripeptide facilitates controlled, targeted copper availability in wound and repair sites, avoiding the toxicity associated with free ionic copper while enabling enzymatic activity
• GHK-Cu promotes angiogenesis through upregulation of VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) expression — a mechanism that overlaps with and reinforces TB-500’s angiogenic activity, representing one of the key synergistic interactions within the GLOW formulation

Skin and Wound Healing Applications

• In controlled clinical dermatology studies, GHK-Cu-treated skin demonstrated 70% improvement in collagen density versus 50% with vitamin C and 40% with retinoic acid — the most extensive head-to-head clinical comparison data available for any topical regenerative peptide
• Injectable GHK-Cu acts systemically rather than locally, with the potential to deliver collagen-stimulating and gene-modulatory effects beyond the skin to connective tissues, tendons, and organ systems

Component 2: TB-500 (Thymosin Beta-4 Fragment Ac-LKKTETQ) — 10 mg

TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of thymosin beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide ubiquitously expressed in human and animal tissues. Thymosin beta-4 was originally isolated from the thymus and is now understood to be one of the most highly conserved and abundant intracellular peptides in eukaryotic cells, playing a central role in actin cytoskeleton dynamics, cell migration, and tissue repair responses. TB-500 is not identical to full-length thymosin beta-4 but retains the critical actin-binding domain responsible for the majority of its regenerative activity.

Actin Sequestration and Cell Migration

• TB-500’s primary molecular mechanism is G-actin sequestration — binding to monomeric (G) actin and preventing its polymerization into filamentous (F) actin, thereby regulating actin dynamics at the leading edge of migrating cells
• By modulating the G-actin/F-actin equilibrium, TB-500 accelerates cell migration of keratinocytes, endothelial cells, and fibroblasts into wound sites — a rate-limiting step in tissue repair that is directly addressed by TB-500 and not by either GHK-Cu or BPC-157
• Stem cell activation and mobilization: Thymosin beta-4 promotes the release and activation of endogenous progenitor cells from bone marrow, including endothelial progenitor cells that contribute to neovascularization at repair sites
• Differentiation of satellite cells (muscle stem cells) into mature myofibers has been demonstrated in animal models, providing the mechanistic rationale for TB-500’s proposed utility in muscle repair and recovery

Angiogenesis and Vascular Repair

• TB-500 stimulates angiogenesis through multiple parallel pathways: direct promotion of endothelial cell migration (actin-mediated), upregulation of VEGF receptor expression, and mobilization of endothelial progenitor cells from bone marrow
• This mechanism overlaps with GHK-Cu’s VEGF upregulation, creating a convergent angiogenic signal within the GLOW formulation that may produce additive neovascularization effects greater than either peptide alone
• Improved blood vessel density at repair sites enhances oxygen and nutrient delivery, accelerating the downstream healing cascade

Anti-inflammatory and Anti-apoptotic Effects

• TB-500 has demonstrated potent anti-inflammatory effects in multiple preclinical models, suppressing NF-κB activation, reducing macrophage infiltration, and lowering TNF-α and IL-1β production at injury sites
• Anti-apoptotic signaling: Thymosin beta-4 activates the Akt/PI3K survival pathway, protecting cells from programmed cell death in the aftermath of ischemic or traumatic injury — a mechanism with potential cardioprotective applications supported by cardiac repair animal studies
• Phase 2 clinical trial data in severe dry eye disease (a meaningful human model of inflammatory tissue dysfunction) demonstrated both safety and clinically meaningful symptom improvement, providing the most robust human evidence of in vivo activity for thymosin beta-4

Component 3: BPC-157 (Body Protection Compound-157) — 10 mg

BPC-157 is a synthetic pentadecapeptide (15 amino acids) with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, originally derived from a portion of the human gastric juice protein BPC (Body Protection Compound). It was developed and extensively studied by Professor Predrag Sikiric at the University of Zagreb in Croatia, where the majority of the published preclinical evidence was generated. BPC-157 has the broadest organ-system profile of the three GLOW components, with demonstrated cytoprotective activity across gastrointestinal, musculoskeletal, neurological, and vascular tissues.

Nitric Oxide (NO) Pathway Modulation

• BPC-157’s most well-characterized molecular mechanism is upregulation of endothelial nitric oxide synthase (eNOS) and modulation of the NO signaling pathway, producing vasodilatory and cytoprotective effects across multiple organ systems
• NO-mediated effects include: microvascular dilation at repair sites, inhibition of platelet aggregation, and activation of downstream healing mediators including VEGF — reinforcing the angiogenic convergence already produced by GHK-Cu and TB-500
• The NO pathway connection also provides a plausible mechanism for BPC-157’s gastroprotective effects, where NO-driven mucosal vasodilation and prostaglandin upregulation protect the gastric and intestinal lining from ulceration and ischemic damage

Growth Factor Receptor Upregulation

• BPC-157 upregulates the expression of EGF (epidermal growth factor) receptor and VEGF receptor at injury sites — a receptor-level amplification mechanism that enhances tissue sensitivity to endogenous growth factor signaling rather than introducing exogenous growth factors
• FAK (focal adhesion kinase) and paxillin pathway activation promotes fibroblast and tendon cell proliferation — the mechanistic basis for BPC-157’s extensively documented tendon and ligament healing activity in preclinical models

Gastrointestinal and Systemic Cytoprotection

• BPC-157’s most well-evidenced preclinical efficacy is in gastrointestinal healing: demonstrated acceleration of gastric ulcer healing, protection against NSAID-induced GI damage, resolution of inflammatory bowel lesions, and intestinal anastomosis healing in rodent and porcine models
• Systemic cytoprotection extends to musculoskeletal tissue: bone, tendon, ligament, and muscle healing acceleration has been consistently demonstrated across dozens of animal model studies
• Neuroprotection: BPC-157 has demonstrated protective effects in traumatic brain injury, spinal cord lesion, and peripheral nerve injury models — the broadest neuroprotective preclinical profile of the three GLOW components
• In the GLOW context, BPC-157 at the 10 mg dose contributes the formulation’s primary GI mucosal and systemic cytoprotective layer — a mechanistic dimension not addressed by GHK-Cu or TB-500

The three components of GLOW collectively represent a substantial body of preclinical research and a modest but growing human clinical data set — distributed very unevenly across the three compounds and their potential indications. GHK-Cu has the strongest topical human clinical evidence (wound healing, skin collagen); TB-500/thymosin beta-4 has the most meaningful human Phase 1–2 safety and activity data (Phase 1 in healthy subjects; Phase 2 in dry eye disease); and BPC-157 has the largest volume of preclinical data but the fewest completed controlled human trials of any of the three.

Critically, no clinical trial data exists for any combination of GHK-Cu + TB-500 + BPC-157 at any dose or ratio. The GLOW combination’s pharmacological rationale is mechanistically coherent but has not been subjected to formal combination safety or efficacy evaluation in human subjects.

GHK-Cu Research Evidence

Pickart L. (1973, Journal of Experimental Medicine) first described GHK’s natural occurrence in human plasma and its biological activity, establishing it as an endogenous wound-healing signal — the foundational discovery underpinning all subsequent GHK-Cu research.

Leyden J, et al. (Clinical dermatology, 1990s) conducted controlled clinical trials of GHK-Cu topical preparations in human subjects, including the pivotal skin collagen density study demonstrating 70% collagen improvement with GHK-Cu versus 50% with vitamin C and 40% with retinoic acid in human thigh skin biopsies — the most direct human clinical evidence of GHK-Cu’s ECM-remodeling activity.

Pickart L, et al. (2018, Journal of Aging Research and Clinical Practice) published a comprehensive review documenting GHK-Cu’s ability to regulate 31.2% of human genes — the largest genomic footprint of any single peptide in the published literature — and provided mechanistic framing for its broad tissue-repair and anti-aging effects.

Wound healing clinical evidence: Multiple controlled dermatological wound-healing studies across the 1990s–2010s documented GHK-Cu acceleration of wound closure, reduction of scar formation, and improvement in tissue organization — generating the clinical evidence base that supported GHK-Cu’s use in medical-grade wound care products.

TB-500 Research Evidence

Sanders MC, et al. (Biochemistry, 1992) and foundational studies characterized thymosin beta-4’s actin-binding mechanism, confirming the Ac-LKKTETQ sequence as the pharmacophore responsible for G-actin sequestration and cell migration promotion.

Phase 1 safety trial (thymosin beta-4): A formal Phase 1 multiple ascending dose study in healthy human volunteers confirmed thymosin beta-4 (full-length) was well tolerated at all doses studied with no dose-limiting toxicities — the foundational human safety data, though generated for full-length Tβ4 rather than the TB-500 heptapeptide fragment specifically.

Phase 2 dry eye trial (Cornea, 2012): A randomized, double-blind, placebo-controlled Phase 2 trial of thymosin beta-4 eye drops in patients with moderate-to-severe dry eye disease demonstrated both safety and statistically significant improvement in corneal staining scores and symptom measures — the most rigorous published human efficacy evidence for any thymosin beta-4 formulation.

Cardiac repair evidence: Multiple peer-reviewed animal studies demonstrated thymosin beta-4’s ability to activate dormant epicardial progenitor cells following myocardial infarction, producing measurable cardiac functional recovery — an effect that prompted human cardiac repair clinical interest, though no Phase 3 data is available as of May 2026.

Important distinction: TB-500 (the heptapeptide fragment Ac-LKKTETQ) has no independent controlled clinical trial data in humans as of May 2026. All human evidence is derived from studies of full-length thymosin beta-4, which is pharmacologically related but not identical. The BSCG (Banned Substances Control Group) has explicitly noted this evidence gap.

BPC-157 Research Evidence

Sikiric P, et al. (University of Zagreb, 1990s–2020s): The vast majority of BPC-157’s published evidence derives from Dr. Predrag Sikiric’s research group — representing an unusually narrow provenance for a compound with a large published literature. Over 100 animal model studies document BPC-157’s effects on GI healing, tendon repair, bone healing, and neuroprotection. Independent replication of these findings in other research centers is limited.

Animal model highlights:

• Tendon-to-bone healing: Accelerated healing in rat Achilles tendon transection models at doses translating to approximately 2–10 mcg/kg in humans — below the GLOW formulation’s 10 mg flat dose
• Gastric ulcer healing: Consistent acceleration of ulcer resolution across multiple rodent models of NSAID-induced, stress-induced, and surgical ulceration
• Inflammatory bowel lesions: Resolution of experimentally induced colitis in rat models

Human clinical trial status: As of May 2026, no completed, published randomized controlled trial of BPC-157 in human subjects exists in the peer-reviewed literature. A Phase 2 trial in short bowel syndrome was registered (PLX-PAD; PharmaPlexus) but did not produce published results. A new trial evaluating BPC-157 for acute hamstring muscle strain was registered on ClinicalTrials.gov in February 2026 (NCT07437547), representing early-stage contemporary interest — but no results are available. McGill University’s Office for Science and Society has characterized the human evidence as a “near-total lack of proof” as of 2026.

Clinical Development

No active FDA-registered clinical development program exists for any GLOW combination of GHK-Cu, TB-500, and BPC-157 at any dose ratio as of May 2026:

• GHK-Cu (non-injectable) holds the most favorable regulatory position of the three components, with a robust topical wound-care clinical evidence base and commercial history
• Thymosin beta-4 (full-length) has undergone Phase 1–2 human trials for specific indications (dry eye, cardiac repair); TB-500 as the isolated heptapeptide fragment has not been formally studied in human trials
• BPC-157 has no completed or published controlled human clinical trial; a gov registration for musculoskeletal injury (NCT07437547, 2026) represents the earliest formal human trial initiation
• No sponsor has filed a combined product IND, NDA, or BLA for any GHK-Cu + TB-500 + BPC-157 combination product with the FDA

Regulatory Status

FDA (United States) — Three Distinct Positions:

The three GLOW components occupy different and individually evolving regulatory positions under the FDA’s 503A bulk drug substance framework as of May 2026:

GHK-Cu:

• Non-injectable GHK-Cu: Returned to Category 1 (503A eligible substances under evaluation) in May 2026 following FDA action consistent with the RFK Jr. February 2026 announcement; non-injectable compounding by licensed 503A pharmacies with a valid prescription is moving toward being permitted pending formal listing
• Injectable GHK-Cu: Remains on Category 2 (significant safety concerns); the PCAC review for injectable GHK-Cu is scheduled for the second PCAC session, expected before February 2027 — not the July 23–24, 2026 session
• The GLOW formulation specifies no route of administration in its naming convention, but the 50/10/10 mg dosing is consistent with injectable systemic use; at that dose and route, injectable GHK-Cu remains a Category 2 substance as of May 2026

TB-500:

• Removed from Category 2 effective April 23, 2026, following withdrawal of the original nomination
• Not added to Category 1; currently in a regulatory gray zone — neither explicitly prohibited nor formally authorized for compounding
• PCAC review scheduled for July 23, 2026 (alongside BPC-157, KPV, and MOTs-C); PCAC recommendation is non-binding; formal rulemaking would follow
• TB-500 is not FDA-approved for any indication; it is not listed in USP/NF monographs; it is not a component of any FDA-approved drug product

BPC-157:

• Removed from Category 2 effective April 23, 2026, following withdrawal of nominations
• Not added to Category 1; identical gray-zone status to TB-500
• PCAC review scheduled for July 23, 2026; binding regulatory determination remains pending
• BPC-157 is not FDA-approved for any indication; not listed in USP/NF monographs; not a component of any approved drug product
• The FDA Law Blog has explicitly noted that removal from Category 2 is “a step, not a clearance,” and that formal rulemaking is what ultimately governs compounding eligibility

WADA (Anti-Doping): All three GLOW components are prohibited in competitive sport under the 2026 WADA Prohibited List (effective January 1, 2026):

• GHK-Cu: Prohibited under S0 (Non-Approved Substances) — applicable to both injectable and non-injectable forms; not approved for human therapeutic use in any jurisdiction
• TB-500: Prohibited under S2 (Peptide Hormones, Growth Factors, Growth Factor Mimetics, and Related Substances) — explicitly listed or covered by class prohibition; prohibited at all times both in- and out-of-competition
• BPC-157: Prohibited under S0 (Non-Approved Substances); also listed by name in some versions of the WADA prohibited list annotations. USADA and DoD Anti-Doping offices have specifically named BPC-157 as a prohibited substance

Any athlete subject to anti-doping rules who uses GLOW — regardless of intended therapeutic purpose or route of administration — faces a potential anti-doping rule violation across all three components. No TUE pathway is available for any GLOW component.

International:

• EMA (EU): No approval for any GLOW component in combined or individual therapeutic form
• TGA (Australia): No approved status for any component; Australia has applied restrictions on various unregulated peptide products
• Health Canada / PMDA (Japan): No approved status
• All three components are available globally through unregulated research chemical vendors; none of these supply chains operates under cGMP oversight applicable to injectable human-use products

The safety profile of GLOW must be assessed both by individual component and by combination — recognizing that no human safety data exists for the GHK-Cu + TB-500 + BPC-157 combination at any dose ratio. Individual component safety data varies considerably in depth and quality: GHK-Cu has the most developed human safety record (decades of topical clinical use); TB-500/thymosin beta-4 has Phase 1 human safety data for the full-length peptide; and BPC-157 has no controlled human safety data whatsoever. All adverse effect characterization below for BPC-157 is therefore extrapolated from animal studies and case reports from unregulated use.

GHK-Cu Safety Profile

Well-established from clinical and topical use:

• Topical/non-injectable: Excellent tolerability record across decades of cosmetic and wound care applications; skin irritation and contact sensitivity are the primary adverse effects, both rare and mild
• Injectable GHK-Cu: Safety data is substantially more limited; the FDA specifically cited immunogenicity risk due to potential for aggregation and peptide-related impurities as the basis for Category 2 classification of the injectable route
• Copper toxicity: At the 50 mg dose in the GLOW formulation (the highest dose component), copper delivery considerations are relevant — though GHK’s chelation of Cu²⁺ is designed to prevent free-ion copper toxicity; systemic copper overload is a theoretical concern at supraphysiologic doses without human dose-ranging data for injectable use
• No serious adverse events have been reported in the published dermatological literature for topical or wound-care applications

TB-500 Safety Profile

From Phase 1 (full-length thymosin beta-4 data):

• Phase 1 studies confirmed well-tolerated profile at all doses studied for full-length thymosin beta-4 with no dose-limiting toxicities; mild-to-moderate adverse events only
• Important caveat: Phase 1 data is for full-length 43-amino acid thymosin beta-4, not for the TB-500 heptapeptide fragment (Ac-LKKTETQ); the safety equivalence of the fragment to the full-length peptide has not been established in controlled human trials
• Theoretical oncological concern: Thymosin beta-4 promotes cell migration, angiogenesis, and stem cell mobilization — biological processes that, in the context of pre-existing malignancy, could theoretically promote tumor growth, invasion, or metastasis. This is an uncharacterized and unquantified risk in human subjects
• No controlled human safety data exists specifically for TB-500 (the fragment); its unregulated use profile in athletes and wellness patients represents real-world exposure without systematic safety monitoring

BPC-157 Safety Profile

From animal studies and case report surveillance (no controlled human data):

• Animal studies characterize BPC-157 as well-tolerated at doses up to 10 mcg/kg in rodents with no observable toxicity in standard acute and sub-chronic exposure paradigms; significant extrapolation to humans at the 10 mg flat dose in GLOW is required
• No dose-ranging safety study in humans has been conducted or published; the 10 mg dose in GLOW is not evidence-based from human pharmacokinetic or safety data
• Theoretical oncological concern (shared with TB-500): BPC-157’s pro-angiogenic and pro-proliferative mechanisms raise the same theoretical risk of tumor promotion in patients with pre-existing malignancy as TB-500; this risk has not been evaluated in any human study
• Drug interaction profile: BPC-157’s NO-pathway modulation may interact with vasodilatory medications, antihypertensives, and PDE5 inhibitors; no formal drug interaction studies have been conducted
• WADA’s OPSS (Operation Supplement Safety) has characterized BPC-157 as a substance whose “safety and effectiveness have not been thoroughly evaluated in humans”

Combination Safety Considerations

The GLOW formulation presents additional safety uncertainties beyond the individual component profiles:

• No human combination safety data: The pharmacokinetic interactions, additive or synergistic adverse effects, and immune response profile of the GHK-Cu + TB-500 + BPC-157 combination have not been evaluated in any controlled study
• Additive pro-angiogenic signaling: All three components stimulate angiogenesis through convergent pathways (VEGF upregulation, endothelial cell migration, eNOS activation); the combined effect on neovascularization could be substantially greater than any individual component — a potentially desirable feature for tissue repair but an uncharacterized risk in patients with occult malignancies, diabetic retinopathy, or other angiogenesis-sensitive conditions
• Immunogenicity risk amplification: The 50 mg GHK-Cu dose represents the highest individual component load in GLOW; injectable peptide combinations increase the overall aggregation and immunogenicity risk surface relative to single-peptide products
• Manufacturing quality in unregulated supply chains: No cGMP manufacturing oversight applies to any GLOW combination product currently available outside of clinical trials; contamination with residual TFA, endotoxins, heavy metals, and microbial load represent serious injection safety risks; identity, purity, and dose accuracy of all three components cannot be verified through unregulated peptide vendors

1. Pickart L. (1973). Human plasma fractions stimulating the growth of cultured mammalian cells. Journal of Experimental Medicine, 138(1), 103–117. https://doi.org/10.1084/jem.138.1.103
2. Pickart L & Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in Human Skin. Journal of Aging Research and Clinical Practice. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
3. Pickart L, et al. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
4. Goldstein AL & Kleinman HK. (2015). Advances in the basic and clinical applications of thymosin β4. Expert Opinion on Biological Therapy, 15(Suppl 1), S139–S145. https://pubmed.ncbi.nlm.nih.gov/26087973/
5. Sosne G, et al. (2012). Thymosin β4 significantly reduces scarring and grafting requirements in patients with severe burn injuries. Cornea (Phase 2 dry eye results). https://pubmed.ncbi.nlm.nih.gov/22074294/
6. Ho EN, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(Suppl 1), S1–S6. https://pubmed.ncbi.nlm.nih.gov/22074294/
7. Sanders MC, et al. (1992). Thymosin β4 (Fx Peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences, 89(10), 4678–4682.
8. Sikiric P, et al. (Multiple years, 1990s–2020s). BPC-157 research program publications. University of Zagreb, Croatia. Summary in: Current Pharmaceutical Design. https://pubmed.ncbi.nlm.nih.gov/
9. BSCG (Banned Substances Control Group). (2026, February). TB-500: Status, Risks, and Bans in Sport and Military. https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
10. USADA / OPSS. (2025). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
11. S. Food and Drug Administration. (2026, May). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Updated Category List. https://www.fda.gov/media/94155/download
12. S. Food and Drug Administration. (2026, April 16). Pharmacy Compounding Advisory Committee Meeting Notice — July 23–24, 2026. Federal Register. https://www.federalregister.gov/documents/2026/05/01/2026-08552
13. The FDA Law Blog. (2026, April 20). FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
14. World Anti-Doping Agency. (2025). 2026 WADA Prohibited List, S0 and S2 (effective January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
15. gov. (2026). BPC-157 for Acute Hamstring Muscle Strain Repair. NCT07437547. https://clinicaltrials.gov/study/NCT07437547